Nuvigil action date extension
This article was originally published in Pharmaceutical Approvals Monthly
Executive Summary
FDA's revised user fee date for Cephalon's excessive daytime sleepiness agent Nuvigil (armodafinil) is April 30 following a 90-day extension. The agency deemed additional information, submitted in October, to be a major amendment to Cephalon's NDA. The firm maintains that it does not expect further delays and continues to expect a mid-2006 launch. Nuvigil is a follow-on compound to Cephalon's sleepiness agent Provigil (modafinil), which could see generic competition by mid-2006...
You may also be interested in...
Nuvigil Label Likely To Include Safety Information From Sparlon Trials
Final approved labeling for Cephalon’s Nuvigil (armodafinil) will likely include results of an FDA safety review for the firm’s other pending product, attention deficit hyperactivity disorder treatment Sparlon (modafinil).
Cephalon To File Gabitril Generalized Anxiety Disorder Claim By Mid-Year
Cephalon plans to file an sNDA by mid-year for expanded use of its anti-seizure medication Gabitril to treat generalized anxiety disorder, pending the outcome of Phase III trials
‘Clear’ Is In The Eye Of The Beholder, New York, CRN Argue In Age-Restricted Sales Litigation
CRN’s request for clarification, as it continues litigating complaint in US District Court for Southern New York, highlights what it contends is vague and overly general language in the legislation passed in October with a 22 April effective date.